The Women’s Health Deficit – How the FemTech Boom is Fixing a Century of Medical Bias.

It’s worth taking a moment to consider this thought experiment. Imagine creating one of the world’s most sophisticated technological systems—layered, intricate, and capable of amazing feats—and then choosing, almost as an afterthought, to never thoroughly examine its operation. For the better part of a century, that is essentially what Western medicine did with female biology. Half of the world’s population is viewed as a male default variation. Every clinic and examination room where a woman describes her symptoms and watches her doctor reach for the closest approximation of an answer is still feeling the effects of that decision.

What has changed, both gradually and abruptly, is that women are now creating their own solutions. There are currently over 200 startups worldwide in the FemTech sector, which is short for the group of tech firms creating products especially for women’s health. These startups deal with everything from menstrual tracking to fertility monitoring to menopause management.

The amount of money entering this market is substantial. The focus is increasing. And the underlying frustration that has been fueling it for decades has been quietly building in pharmacy lines, waiting rooms, and online forums where women have been exchanging notes about conditions that medicine has either ignored, undertreated, or simply never bothered to thoroughly investigate.

The menopause narrative is arguably the best example of how pervasive the issue is. For a long time, Western biomedicine treated menopause, which affects about half of the world’s population at some point in their lives, as a hormone deficiency. An issue to be handled. a list of symptoms that need to be addressed with medication. Weight gain, mood swings, hot flashes, and night sweats are all presented as malfunctions rather than as a typical, if difficult, transition.

For years, researchers at Sweden’s KTH Royal Institute of Technology worked closely with women going through menopause. What these women described was more complex, unfamiliar, and human than any symptom tracker could record: a mix of physical change, identity shifting, social pressure, and, sometimes, unexpected relief. There was no box for that on the biomedical checklist.

FemTech businesses filled that void. The Grace bracelet and other similar devices were made to identify and cool hot flashes. Apps such as MySysters and myPause use lifestyle data and tracked experiences to provide tailored advice. High-end apparel companies started focusing on women who had night sweats. This appears to be progress at first glance, and it is in some respects. People are paying attention. Products are being manufactured. Instead of being viewed as a group worth putting up with, women are being viewed as a market worth catering to. It’s difficult to ignore the fact that this change, despite its commercial motivations, has led to the creation of things that were previously unimaginable.

However, the FemTech boom is accompanied by a tension that is not as frequently discussed as the success stories. Feminist design scholars who have closely examined these products are among the researchers who are concerned that some FemTech tools are doing more than just freeing women from medical neglect. In certain instances, they might be applying the same medicalizing reasoning to new packaging. An app that reduces menopause to a predetermined list of symptoms that can be tracked and asks users to chart their “conditions” so that a doctor can review them doesn’t necessarily follow a different philosophy than the one it replaces. The terms “empowerment,” “wellness,” and “taking control” may have changed, but the underlying presumption that the female body is a problem that needs ongoing monitoring and control may have remained mostly the same.

This does not imply that FemTech is going in the wrong direction. It implies that direction is just as important as destination. Better symptom trackers were not requested by the women who took part in KTH’s design workshops. Instead of classifying and rectifying their experiences, they requested tools that made room for them. The “cocoon,” an evocative term for something medicine seldom provides—an environment designed to accompany you rather than to fix you—was one of the design concepts they created during a workshop. That is a distinct design philosophy that merits careful consideration.

Even though its full implications are still not fully understood, the larger story of women’s health as a research gap is by now fairly well documented. In the past, the majority of participants in medical trials were men, and the results were extrapolated to women with differing degrees of accuracy. For years, endometriosis, polycystic ovarian syndrome, and autoimmune disorders—conditions that disproportionately affect women—were chronically underfunded and understudied. Looking back, it seems more likely that institutional laziness—a preference for what was simpler to measure and less expensive to standardize—was the driving force behind the system’s creation than malevolent intent. Delays in diagnosis, insufficient treatments, and a persistent sense of not being fully believed were the consequences of this preference for women.

At its best, FemTech corrects that history both commercially and culturally, making medicine recognize that female biology is a fundamental subject that the field somehow managed to treat like a specialty rather than a specialty. It remains to be seen if the industry will be able to withstand the temptation to adopt the same reductive mindset that it developed in response to. Technology is advancing more quickly than its underlying philosophy. It’s still unclear if the objective is to truly comprehend women’s health in all of its complexity or if it’s just to profit from the annoyance caused by a lack of knowledge. It is possible for both to be true simultaneously. Most likely, they are.